Back to top
more

Hims & Hers Health (HIMS)

(Real Time Quote from BATS)

$56.49 USD

56.49
95,764,901

-6.86 (-10.83%)

Updated Aug 5, 2025 03:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (71 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for BBSC

Zacks Equity Research

Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FNY

Debanjana Dey headshot

Hims & Hers vs. Amwell: Which Telehealth Stock Is the Better Buy?

by Debanjana Dey

HIMS targets personalized, AI-powered care with bold obesity moves, while AMWL bets on system-wide integration via Converge and top-tier health alliances. Who wins? Let's see.

Zacks Equity Research

Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds

by Zacks Equity Research

ABT sees a 21.6% jump in CGM sales and growing global diagnostics demand, while FX and macro pressure temper its outlook.

Zacks Equity Research

Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?

by Zacks Equity Research

ILMN unveils PromoterAI to decode noncoding genetic variants, aiming to drive breakthroughs in rare disease diagnosis.

Zacks Equity Research

Thermo Fisher Launches New Spectral Flow Cytometer: Stock to Gain?

by Zacks Equity Research

TMO unveils spectral-enabled Attune Xenith Flow Cytometer to streamline workflows and boost research accuracy.

Zacks Equity Research

Bruker Stock to Gain From the Launch of MOVE-T Liquid Dairy Analyzer

by Zacks Equity Research

BRKR unveils the MOVE-T analyzer to boost quality and efficiency in the dairy industry, setting new standards for precision and reliability.

Zacks Equity Research

Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer

by Zacks Equity Research

HIMS launches six-month Wegovy access at $549/month, aiming to expand affordable obesity care with holistic weight loss solutions.

Zacks Equity Research

Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?

by Zacks Equity Research

Japan approves ILMN's TSO Comprehensive, marking a key step forward in global precision oncology adoption and clinical use.

Zacks Equity Research

TMO Stock Set to Gain From the Launch of New Narcotic Analyzers

by Zacks Equity Research

Thermo Fisher launches new TruNarc analyzers to help law enforcement quickly detect 1,200+ substances, boosting field safety and drug interdiction efforts.

Zacks Equity Research

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JSMD

Zacks Equity Research

RVTY Stock Falls Despite the Latest Launch of Automated Instrument

by Zacks Equity Research

Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.

Zacks Equity Research

Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock

by Zacks Equity Research

EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.

Zacks Equity Research

MMSI Stock Gains Following Latest Merger to Boost Hemostasis Portfolio

by Zacks Equity Research

Merit Medical aims to provide an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology.

Zacks Equity Research

AST Business Growth & Strategic Acquisitions Support STERIS Stock

by Zacks Equity Research

STE frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses.

Sweta Killa headshot

5 Single-Stock ETFs That Doubled in a Month

by Sweta Killa

We have highlighted five single-stock ETFs that have doubled over the past month amid a historic Wall Street comeback.

Zacks Equity Research

Are Medical Stocks Lagging DBV Technologies (DBVT) This Year?

by Zacks Equity Research

Here is how DBV Technologies S.A. (DBVT) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.

Zacks Equity Research

Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software

by Zacks Equity Research

ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.

Zacks Equity Research

ZBH Stock to Gain From Buyouts and Innovations Amid Macro Issues

by Zacks Equity Research

Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.

Zacks Equity Research

Abbott Reveals Positive Outcome From REFLECT Studies, Stock Climbs

by Zacks Equity Research

Per REFLECT studies, ABT's Libre technology is the first CGM linked to fewer hospitalizations for heart complications in people with diabetes.

Zacks Equity Research

Here's Why You Should Add Hims & Hers Stock to Your Portfolio Now

by Zacks Equity Research

Hims & Hers leads with AI-powered, personalized health plans (over 70% of new users opt in). Recurring revenues surge as tailored care drives loyalty.

Debanjana Dey headshot

Hims & Hers Stock Declines 3.1% in 3 Months: Is it a Buy Now?

by Debanjana Dey

HIMS is expanding its health and wellness products and services and increasing its focus on AI to solidify its footing. However, macro challenges may hurt performance.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Sanghamitra Saha headshot

Bet on Winning DuPont Analysis & Pick 3 Top Stocks

by Sanghamitra Saha

Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).

Zacks Equity Research

Omnicell's New Perioperative Clinic Setting Products May Boost Stock

by Zacks Equity Research

OMCL unveils new offerings for the perioperative and clinic setting.